672 results on '"Naidoo, Jarushka"'
Search Results
102. Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2
103. 514. Association Between Antibiotic Exposure and Clinical Outcomes of Immune Checkpoint Inhibition
104. 1244 Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events
105. Pneumonitis From Anti--PD-1/PD-L1 Therapy
106. Outcomes of immunotherapy-related hepatotoxicity from a multi-disciplinary toxicity team
107. Cardiovascular complications of immune checkpoint inhibitors for cancer
108. Correction to: The gut microbiome, immune check point inhibition and immune‑related adverse events in non‑small cell lung cancer
109. Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy
110. Sex-specific differences in immunogenomic features of response to immune checkpoint blockade
111. From expert recommendations to multidisciplinary team decisions: a way to set out the novel perioperative options for patients with non-small-cell lung cancer
112. Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer
113. Seq-ing the SINEs of Central Nervous System Tumors in Cerebrospinal Fluid DNA
114. An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis
115. Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.
116. Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081.
117. The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
118. Toxicity of concurrent and adjuvant temozolomide in patients with glioblastoma multiforme (GBM).
119. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
120. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management
121. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
122. Optimizing the Delivery of Antineoplastic Therapies to the Central Nervous System
123. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
124. Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2.
125. Outcomes of immunotherapy-related hepatotoxicity from a multi-disciplinary toxicity team.
126. Double trouble: rare double-mutant EGFR mutant adenocarcinoma
127. Corrigendum to “Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC” [Cancer Treat. Rev. 104 (2022) 102350]
128. Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC
129. Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors
130. Correction to: The cost of cancer care: how far would you go for a trial?
131. The cost of cancer care: how far would you go for a trial?
132. Mutation status and postresection survival of patients with non–small cell lung cancer brain metastasis: implications of biomarker-driven therapy
133. KRAS-Mutant Lung Cancers in the Era of Targeted Therapy
134. Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
135. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
136. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
137. 327 Development and validation of a neoantigen-specific T cell gene signature to identify antitumor T cells in lung cancer and melanoma
138. 237 Infectious complications in patients with non-small cell lung cancer treated with anti-PD(L)1 immune checkpoint inhibitors
139. 836 Murine fecal microbiota transfer models colonize human microbes selectively and reveal transcriptional pathways associated with response to neoadjuvant checkpoint inhibitors
140. Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
141. Adaptive Neoadjuvant Chemotherapy Guided by 18F-FDG PET in Resectable Non–Small Cell Lung Cancers: The NEOSCAN Trial
142. Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials.
143. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial
144. Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis
145. Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies
146. Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
147. Abstract 27: Early dynamics in peripheral blood immune cell subsets and ctDNA are predictive of outcome to immunotherapy
148. Abstract 1668: Longitudinal dynamics of circulating tumor DNA and plasma proteomics predict clinical outcomes to immunotherapy in non-small cell lung cancer
149. Abstract 1617: Sex-specific genomic determinants of response to immunotherapy
150. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.